Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 20:8:F1000 Faculty Rev-1665.
doi: 10.12688/f1000research.19144.1. eCollection 2019.

Psoriatic arthritis

Vanessa Ocampo D  1 , Dafna Gladman  1   2
Affiliations
Review

Psoriatic arthritis

Vanessa Ocampo D et al. F1000Res. .

Abstract

Psoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2-4% in western adults, and 20--30% of psoriasis patients will develop psoriatic arthritis (PsA). PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally with a peak age at onset of 40 and 50 years. It is a diverse disease that affects multiple organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease. Given this heterogeneity, its diagnosis has been difficult. Here we present an updated review of its classification criteria CASPAR (classification criteria for PsA), use of screening tools to aid in early diagnosis, recent findings on pathogenesis, and new therapeutic approaches including new biologic medications.

Keywords: biomarkers; pathogenesis; psoriatic arthritis; treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DG has received consulting fees and/or grant support from Abbvie, Amgen, Bristol-Myers Squibb (BMS), Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and Union Chimique Belge (UCB). VOD has no competing interests to disclose.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Zlatkovic-Svenda M, Kerimovic-Morina D, Stojanovic RM: Psoriatic arthritis classification criteria: Moll and Wright, ESSG and CASPAR -- a comparative study. Acta Reumatol Port. 2013;38(3):172–8. - PubMed
    1. Kurd SK, Gelfand JM: The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218–24. 10.1016/j.jaad.2008.09.022 - DOI - PMC - PubMed
    1. Alinaghi F, Calov M, Kristensen LE, et al. : Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19. 10.1016/j.jaad.2018.06.027 - DOI - PubMed
    1. Eder L, Haddad A, Rosen CF, et al. : The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis Rheumatol. 2016;68(4):915–23. 10.1002/art.39494 - DOI - PubMed
    1. Husni E, Michael M: Oxford textbook of Psoriatic arthritis: Epidemiology of PsA.Oxford university.2018. Reference Source